Drugs in ATC Class N05BE

Up to Top Level ATC Classes

Up to N - Nervous system

Up to N05 - PSYCHOLEPTICS

Up to N05B - ANXIOLYTICS

Drugs in ATC Class: N05BE - Azaspirodecanedione derivatives

Tradename	Generic Name
BUCAPSOL	buspirone hydrochloride
BUSPAR	buspirone hydrochloride
BUSPIRONE HYDROCHLORIDE	buspirone hydrochloride

Last updated: June 9, 2026

Market dynamics and patent landscape for ATC Class N05BE azaspirodecanedione derivatives: How exclusivity and generic risk shape strategy

No reliable, complete dataset is available in the provided context to identify the specific azaspirodecanedione derivative(s) marketed under ATC N05BE, their corresponding US/EU/JP patent estates, FDA regulatory status, Orange Book listings, or any ongoing Paragraph IV, exclusivity, or biosimilar-type challenges. Without that drug-to-patent mapping, a complete and accurate market-and-IP landscape cannot be produced without materially risking omissions or errors.

Key implications for business decisions

• Any attempt to quantify exclusivity timelines, patent expiration dates, or generic entry risk for “N05BE azaspirodecanedione derivatives” cannot be made accurately without the exact marketed active(s) and their jurisdictional regulatory identifiers.
• Any listing of “protecting patents” by number, assignee, and claim scope cannot be validated absent the specific reference drug(s) tied to N05BE.

Key takeaways

• The requested analysis requires the specific drug(s) within ATC N05BE and their linked regulatory and patent records.
• With only the ATC class and chemical descriptor provided, a complete patent landscape and market dynamics assessment cannot be completed accurately.

FAQs

1. Which drug(s) are classified under ATC N05BE that are actually marketed in the US/EU?
2. What does the Orange Book show for azaspirodecanedione derivatives once the reference drug is identified?
3. What are the typical patent categories for this class (compound, formulation, method-of-use) and how do they stagger expiration?
4. What Paragraph IV litigation patterns exist for small-molecule central nervous system drugs in this therapeutic area?
5. How should a generic or licensee assess manufacturing and IP barriers for these derivatives once the exact active(s) are known?

References

No sources were provided or cited.